CompoAtlas

PURE PROFESSIONAL - VITAMIN STRONG PROFESSIONAL

Food supplement declared in France, declaration No 2024-6-1114, decision dated 20 June 2024

PURE PROFESSIONAL - VITAMIN STRONG PROFESSIONAL, from TSUNAMI NUTRITION SRL, is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Olea europaea 62.5 mg per day, Punica granatum 50 mg per day, Pantothenic acid (vitamin B5), Biotin (vitamin B8), Chromium. None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.

Brand
not provided
Food business operator placing the product on the market
TSUNAMI NUTRITION SRL
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Tablet
Daily dose
3 comprimés par jour
Intended populations
Men, Women
Not recommended (according to the manufacturer)
Adolescents (under 18), Breastfeeding women, Pregnant women, Kidney disease, Heart problems, Taking anticoagulants, Taking diabetes medication, Taking thyroid medication

Declaration 142939, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Olea europaea L.FeuilleExtrait sec hydroalcoolique62.5 mg
Punica granatum L.FruitExtrait sec hydroalcoolique50 mg

Other active ingredients

NamePer day
Acide adénosine-5'-phosphoriquenot declared
Acide cytidine-5'-monophosphoriquenot declared
Acide uridine-5'-phosphoriquenot declared
Acide guanosine-5'-phosphoriquenot declared
Resvératrolnot declared
Chlorhydrate d'acétyl-L-carnitinenot declared
L-Carnitine L-Tartratenot declared
Acétylcystéinenot declared
Inositolnot declared
Acide lipoïquenot declared
Bitartrate de cholinenot declared
Ubiquinonenot declared
Pipérinenot declared
Lycopènenot declared
Lutéinenot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
D-pantothenate, calciumPantothenic acid (vitamin B5)no limit (insufficient data)dose annulled by the French Council of State in 2011
D-biotinBiotin (vitamin B8)no limit (insufficient data)dose annulled by the French Council of State in 2011
chromium picolinateChromiumno limit (insufficient data)25 µg
cupric gluconateCopper5,000 µg2,000 µg
ferrous fumarateIron40 mg (safe level)14 mg
pteroylmonoglutamic acidFolate (vitamin B9)1,000 µg200 µg
potassium iodideIodine600 µg150 µg
magnesium salts of citric acidMagnesium250 mg300 mg
manganese gluconateManganese8 mg (safe level)3.5 mg
nicotinamideNicotinamide (vitamin B3)900 mg54 mg
L-selenomethionineSelenium255 µg50 µg
retinyl palmitateVitamin A3,000 µg d'équivalent rétinol800 µg
thiamin hydrochlorideVitamin B1 (thiamine)no limit (insufficient data)dose annulled by the French Council of State in 2011
cyanocobalaminVitamin B12no adverse effect defineddose annulled by the French Council of State in 2011
riboflavinVitamin B2 (riboflavin)no limit (insufficient data)dose annulled by the French Council of State in 2011
pyridoxine hydrochlorideVitamin B612 mg2 mg
L-ascorbic acidVitamin Cno limit (insufficient data)180 mg
cholecalciferolVitamin D100 µg (4,000 IU)5 µg (200 IU)
DL-alpha-tocopheryl acetateVitamin E300 mg30 mg
menaquinoneVitamin Kno limit (insufficient data)dose annulled by the French Council of State in 2011
zinc citrateZinc25 mg15 mg

Additives

E460, E470b, E551, E464, E553b, E463, E170, E1521, E172, E1203

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

Les compléments alimentaires ne doivent pas se substituer à une alimentation variée et équilibrée et à un mode de vie sain. Ne pas laisser à la portée des jeunes enfants. Ne pas dépasser la dose journalière recommandée. Réservé à l'adulte. Déconseillé chez les personnes diabétiques, ainsi que les femmes enceintes et allaitantes. Déconseillé aux personnes souffrant de maladies ayant pour conséquence une accumulation anormale de fer. Usage prolongé déconseillé. Déconseillé aux femmes enceintes ou désireuses de l’être. Déconseillé aux femmes ménopausées. Déconseillé aux personnes souffrant de troubles de la thyroïde. Déconseillé aux personnes sous traitement anticoagulant.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Olea europaea L.
    Read the warning, when it applies and the studies cited

    OLIVE LEAF - OLEA EUROPAEA

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you pregnant or breastfeeding (EMA 2017).

    Sources cited by Health Canada (1)
    • EMA 2017: European Medicines Agency. European Union herbal monograph on Olea europaea L., folium. [Accessed 2024 November 27]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-olea-europaea-l-folium-first-version_en.pdf

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a kidney disorder (EMA 2017).

    Sources cited by Health Canada (1)
    • EMA 2017: European Medicines Agency. European Union herbal monograph on Olea europaea L., folium. [Accessed 2024 November 27]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-olea-europaea-l-folium-first-version_en.pdf

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking other diuretics (EMA 2017).

    Sources cited by Health Canada (1)
    • EMA 2017: European Medicines Agency. European Union herbal monograph on Olea europaea L., folium. [Accessed 2024 November 27]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-olea-europaea-l-folium-first-version_en.pdf

    Known adverse reactions

    Condition of application: All products except those making a diuretic claim.

    When using this product diuretic effect may occur.

    Health Canada monograph dated 19 December 2025

  • Punica granatum L.
    Read the warning, when it applies and the studies cited
  • Acétylcystéine
    Read the warning, when it applies and the studies cited

    N-ACETYL-L-CYSTEINE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have kidney stones (Fauci et al. 1998; Mårtensson et al. 1990).

    Sources cited by Health Canada (2)
    • Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DI, Hauser SL and Longo DL, editors. Harrison's Principles of Internal Medicine, 14th edition. Toronto (ON): McGraw-Hill Health Professions Division; 1998.
    • Mårtensson J, Denneberg T, Lindell Å, Textorius O. Sulfur amino acid metabolism in cystinuria : A biochemical and clinical study of patients. Kidney International 1990;37:143-149. PubMed

    Contraindications

    Do not use if you are taking antibiotics or nitroglycerin (Repchinsky 2008; Cederlund and Märdh 1993; Parry and Neu 1977; Ardissino et al. 1997).

    Sources cited by Health Canada (4)
    • Ardissino D, Merlini PA, Savonitto S, Demicheli G, Zanini P, Bertocchi F, Falcone C, Ghio S, Marinoni G, Montemartini C, Mussini A. Effect of transdermal nitroglycerin or N- acetylcysteine, or both, in the long-term treatment of unstable angina pectoris. Journal of the American College of Cardiology 1997;29(5):941-947. PubMed Randomised trial
    • Cederlund H, Märdh PA. Antibacterial activities of non-antibiotic drugs. Journal of Antimicrobial Chemotherapy 1993;32:355-365. PubMed Review article
    • Parry MF, Neu HC. Effect of N-acetylcysteine on antibiotic activity and bacterial growth in vitro. Journal of Clinical Microbiology 1977;5(1);58-61.
    • Repchinsky C, editor. Compendium of Pharmaceuticals and Specialties. The Canadian Drug Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association; 2008.

    Health Canada monograph dated 19 December 2025

  • Acide lipoïque
    Read the warning, when it applies and the studies cited

    DL-ALPHA-LIPOIC ACID/R-ALPHA-LIPOIC ACID

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Jacob et al. 1999, Konrad et al. 1999, Packer et al. 1995).

    Sources cited by Health Canada (3)
    • Jacob S, Ruus P, Hermann R, Tritschler HJ, Maerker E, Renn W, Augustin HJ, Dietze GJ, Rett K. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radical Biology & Medicine 1999;27(3-4):309-314. PubMed Randomised trial
    • Konrad T, Vicini P, Kusterer K, Höflich A, Assadkhani A, Böhles HJ, Sewell A, Tritschler HJ, Cobelli C, Usadel KH. Alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care 1999;22(2):280-287. PubMed
    • Packer L, Witt EH, Tritschler HJ. Alpha-Lipoic acid as a biological antioxidant. Free Radical Biology & Medicine 1995;19(2):227-250. PubMed Review article

    Applies to products providing 42 milligrams or more DL-alpha-lipoic acid or 21 milligrams or more R-alpha-lipoic acid, per day.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience sweating, paleness, chills, headache, dizziness and/or confusion (as these may be symptoms of serious low blood sugar) (Bae et al., 2013; Gullo et al., 2014; Bresciani et al., 2011; Chang et al., 2009).

    Sources cited by Health Canada (4)
    • Bae SM, Bae MN, Kim EY, Kim IK, Seo MW, Shin JK, Cho SR, Jeong GH. Recurrent Insulin Autoimmune Syndrome Caused by α-Lipoic Acid in Type 2 Diabetes. Endocrinol Metab (Seoul). 2013;28(4):326-330. PubMed
    • Bresciani E, Bussi A, Bazzigaluppi E, Balestrieri G. Insulin autoimmune syndrome induced by α-lipoic acid in a Caucasian woman: case report. Diabetes Care. 2011 Sep;34(9):e146. doi: 10.2337/dc11-0600. DOI
    • Chang HJ, Choi HS, Park MY, Leem SM, Jang YS, Park KS, Lee JM. A case of insulin autoimmune syndrome related to alpha-lipoic acid. Korean J Med 2009;76:600-604.
    • Gullo D, Evans JL, Sortino G, Ira D. Goldfine and Vigneri R. Insulin autoimmune syndrome (Hirata Disease) in European Caucasians taking a-lipoic acid. Clinical Endocrinology 2014;81: 204-209. PubMed

    Health Canada monograph dated 27 June 2025

  • Ubiquinone
    Read the warning, when it applies and the studies cited

    Coenzyme Q10 (UBIQUINONE-10)

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).

    Sources cited by Health Canada (2)
    • Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
    • Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial

    Applies to products providing more than 100 mg of Coenzyme Q10 per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).

    Sources cited by Health Canada (3)
    • Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
    • Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
    • Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report

    Condition of application: Migraine prophylaxis/prevention.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.

    Health Canada monograph dated 31 January 2025

  • Pipérine
    Read the warning, when it applies and the studies cited

    BLACK/WHITE PEPPER - PIPER NIGRUM

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications or any other health products, as black/white pepper/piperine may alter their effectiveness (Han 2011; Srinivasan 2007; Khajuria et al. 2002; Bano et al. 1991).1

    Sources cited by Health Canada (4)
    • Bano G, Raina RK, Zutshi U, Bedi KL, Johri RK, Sharma SC. Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers. European Journal of Pharmacology 1991;41(6):615-7. PubMed
    • Han HK. The effects of black pepper on the intestinal absorption and hepatic metabolism of drugs. Expert Opinion on Drug Metabolism & Toxicology 2011;7(6):721-729. PubMed Review article
    • Khajuria A, Thusu N, Zutshi U. Piperine modulates permeability characteristics of intestine by inducing alterations in membrane dynamics: influence on brush border membrane fluidity, ultrastructure and enzyme kinetics. Phytomedicine 2002;9(3):224-31. PubMed
    • Srinivasan K. Black Pepper and its pungent principle-piperine: a review of diverse physiological effects. Critical Reviews in Food Science and Nutrition 2007;47(8):735-748. PubMed Review article

    1Note: At subtherapeutic quantities, the risk statement regarding the alteration of effectiveness is not required for products providing 25 mg or less Piper nigrum fruit per day for Class II and III applications.

    Condition of application: Improve digestion.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: Vermifuge/anthelmintic.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or persist for more than 2 weeks.

    Health Canada monograph dated 19 December 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “PURE PROFESSIONAL - VITAMIN STRONG PROFESSIONAL: composition and regulation”, https://compoatlas.com/en/supplements/products/142939-pure-professional-vitamin-strong-professional, updated 15 November 2026.

List recorded in 2024. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line